Supernus Pharmaceuticals SUPN Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| APOKYN | $7.73M-48.4% | $9.59M-52.3% | $10.39M-47.7% | $12.82M-25.9% | $14.98M-10.0% | |
| Collaboration revenue (ZURZUVAE) | $27.64M— | $32.83M— | $20.16M— | $0— | $0— | |
| GOCOVRI | $35.24M+14.8% | $38.63M+4.7% | $40.85M+14.6% | $36.66M+15.6% | $30.69M+15.5% | |
| ONAPGO | $8.38M— | $8.84M— | $6.81M— | $1.6M— | $0— | |
| Other | $4.67M-45.6% | $4.77M-31.4% | $7.03M-3.7% | $6.53M-13.4% | $8.58M+18.9% | |
| Oxtellar XR | $7.42M-27.2% | $6.85M-48.1% | $12.02M-59.7% | $11.64M-60.6% | $10.2M-62.1% | |
| Qelbree | $77.84M+20.2% | $80.95M+8.8% | $81.42M+30.6% | $77.55M+30.6% | $64.75M+43.5% | |
| Royalty, licensing, and other revenues | $29.31M+274% | $20.73M+167% | $3.4M-36.9% | $7.46M+28.9% | $7.84M+51.2% | |
| Trokendi XR | $9.48M-26.0% | $8.38M-43.4% | $10.04M-34.4% | $11.19M-34.5% | $12.8M-19.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Supernus Pharmaceuticals break its business down?
- Supernus Pharmaceuticals (SUPN) reports total revenues by product across 9 parts — APOKYN, Collaboration revenue (ZURZUVAE), GOCOVRI, ONAPGO and Other. Each is extracted from the segment footnotes and tracked over time.
- Where does Supernus Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Supernus Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
